ClinicalTrials.gg
CompletedNCT02072278Updated Sep 1, 2015

Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

A Phase 1 interventional study of Vortioxetine 10 mg and Vortioxetine 20 mg in Healthy Men, sponsored by H. Lundbeck A/S. Completed at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-01.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To explore a neurophysiological marker (electroencephalography) of cognitive effect of vortioxetine

02

Conditions studied

  • Healthy Men
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has a normal resting EEG at screening visit
  • The subject is able to perform tasks with an auditory stimulus
  • The subject is not visually impaired - normal prescription glasses are accepted
  • The subject has a normal circadian rhythm, defined as a person who usually wakes between 6:00 and 9:00 a.m. and goes to sleep between 9:00 pm and midnight.

Exclusion criteria

Exclusion Criteria:

  • The subject has worked shifts, including night duty, or has travelled across >3 time zones \<2 weeks prior to the first dose of IMP.

Other inclusion and exclusion criteria may apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg

    encapsulated tablets; 3 daily doses in each treatment period; orally

    Drug: Vortioxetine 10 mg

  • Experimental
    Vortioxetine 20 mg

    encapsulated tablets; 3 daily doses in each treatment period; orally

    Drug: Vortioxetine 20 mg

  • Active comparator
    Escitalopram 15 mg

    encapsulated tablets; 3 daily doses in each treatment period; orally

    Drug: Escitalopram 15 mg

  • Placebo comparator
    Placebo

    capsules; 3 daily doses in each treatment period; orally

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Battery of EEG measurements

    * Peak amplitude and latency of P300 * AUC of qEEG power spectral bands delta, theta, alpha, beta and gamma * AUC of evoked gamma power spectral band * Peak amplitude and latency of N200 * Peak amplitude and latency of error related negativity * Peak amplitudes and latencies in the evoked responses during successful versus non-successful encoding in the verbal memory task between treatments

    Time frame: The EEG task battery will be conducted on Days -1 and starting 6 hours post-dose on Days 1 and 3 of each treatment period.

07

Study locations

1 site
  • FR801
    Rennes, 35000, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014 and a primary completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2014
First posted
Feb 26, 2014
Start
Feb 2014
Primary completionActual
Nov 2014
Last update
Sep 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02072278
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Feb 2014
Primary completion
Nov 2014
Last update
Sep 1, 2015

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion